{"product_id":"dynavax-five-forces-analysis","title":"Dynavax Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDynavax faces moderate supplier power, high regulatory hurdles, and intense rivalry in the vaccine market, with emerging biotech entrants and substitute therapies shaping competitive tension; this snapshot highlights key pressures but omits force-by-force ratings and strategic implications.\u003c\/p\u003e\n\u003cp\u003eUnlock the full Porter's Five Forces Analysis to explore Dynavax’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Dependency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax depends on specialized biological and chemical inputs for CpG 1018 and HEPLISAV-B that must meet GMP and FDA specs, and only a handful of suppliers qualify; as of 2024 roughly 2–4 vendors supplied key oligonucleotides and adjuvant reagents.\u003c\/p\u003e\n\u003cp\u003eThis supplier scarcity gives vendors pricing power—Dynavax reported cost of goods sold at 42% of revenue in 2024, reflecting input-price sensitivity—and single-source leads to timeline risk: a 2023 supplier delay pushed a batch release by 8–12 weeks. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSole-Source Manufacturing Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax relies on third-party contract manufacturing organizations (CMOs) for drug substance and fill-finish; switching CMOs can take 6–18 months and cost millions for regulatory re-validation, so suppliers gain leverage in pricing and timelines. In 2024 Dynavax reported COGS of $67.3M, and single-source CMOs raise risk of production delays and higher per-unit costs, strengthening supplier bargaining power in contract talks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Regulatory Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers must follow FDA cGMP and similar WHO\/EU rules, and audits plus capital upgrades average $5–15m per facility, so only ~30–50 global biologics-grade suppliers meet standards as of 2025, limiting options for Dynavax.\u003c\/p\u003e\n\u003cp\u003eThose high compliance costs raise supplier bargaining power: switching suppliers can take 12–24 months and $2–10m in qualification expenses, reducing Dynavax’s ability to cut input costs or negotiate aggressively.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWhen suppliers hold patents on critical vaccine components, Dynavax faces limited bargaining power and must accept higher input prices; for example, supplier-controlled adjuvant IP can raise cost of goods by an estimated 10–20% versus generic sourcing (industry benchmark, 2024).\u003c\/p\u003e\n\u003cp\u003eThese locked-in supplier relationships reduce Dynavax’s ability to switch vendors quickly, increasing supply risk and margin pressure, especially given the company’s 2024 R\u0026amp;D spend of $72.3M and reliance on specialized inputs for HEPLISAV-B and pipeline candidates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent ownership limits price negotiation\u003c\/li\u003e\n\u003cli\u003eEstimated 10–20% higher COGS vs generic inputs\u003c\/li\u003e\n\u003cli\u003eLocks Dynavax to specific vendors, raising supply risk\u003c\/li\u003e\n\u003cli\u003eAmplifies margin pressure given $72.3M 2024 R\u0026amp;D spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal logistical hiccups and geopolitics have tightened access to specialized lab equipment and reagents, and as of late 2025 biotech supply chain disruptions raised lead times by ~35% vs. 2019, empowering suppliers with inventory.\u003c\/p\u003e\n\u003cp\u003eDynavax often pays premium pricing or accepts longer payment terms to keep commercial manufacturing running; supplier concentration in key inputs gives vendors greater leverage over contract terms and delivery windows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLead times +35% vs. 2019 (late 2025)\u003c\/li\u003e\n\u003cli\u003eInventory-ready suppliers set premium prices\u003c\/li\u003e\n\u003cli\u003eDynavax accepts unfavorable payment\/delivery terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier power lifts Dynavax COGS to 42%, squeezing margins amid long switch times\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier scarcity, regulatory-qualified CMOs, patent-held adjuvant IP, and rising lead times give suppliers strong bargaining power—raising Dynavax’s 2024 COGS to 42% of revenue and COGS $67.3M, adding 10–20% input premium risk and 12–24 month switching timelines that compress margins vs R\u0026amp;D spend $72.3M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS % revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS ($)\u003c\/td\u003e\n\u003ctd\u003e$67.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e$72.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput premium\u003c\/td\u003e\n\u003ctd\u003e10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitch time\u003c\/td\u003e\n\u003ctd\u003e12–24 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Dynavax, this Porter's Five Forces analysis uncovers competitive drivers, supplier and buyer power, entry barriers, substitute threats, and disruptive forces shaping its pricing, profitability, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA clear, one-sheet Porter's Five Forces summary for Dynavax—instantly highlights competitive pressures and regulatory risk to speed strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Large-Scale Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant share of dynavax vaccine revenue comes from bulk buyers like us government agencies procurement programs and large hospital systems which in accounted for roughly public-sector purchases nationally. these purchasers negotiate steep discounts rebates pressuring list prices margins. their ability to reallocate volume competitors or biosimilars gives them strong bargaining power over pricing contract terms.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMajor chains like CVS Health and Walgreens Boots Alliance, which administered roughly 60% of US adult vaccines in 2024, hold strong bargaining power over Dynavax’s HEPLISAV-B because they steer stocking decisions via reimbursement and margin demands.\u003c\/p\u003e\n\u003cp\u003eIf rivals pay better rebates or offer higher gross margins—say a 3–5 percentage-point advantage—these retailers can shift shelf space and administration volume away from HEPLISAV-B, cutting Dynavax revenues tied to pharmacy channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity of Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic and private insurers assess vaccines by cost-effectiveness and outcomes versus current standards; in the US, CDC\/ACIP and Medicare Part B\/Part D coverage decisions hinge on ICER thresholds around $50,000–$150,000 per QALY (2024 guidance used by many payers).\u003c\/p\u003e\n\u003cp\u003eIf Dynavax raises prices sharply, payers may impose step edits, prior authorization, or narrow networks; in 2023, 22% of vaccine claims faced utilization management in commercial plans.\u003c\/p\u003e\n\u003cp\u003eThat pressure forces Dynavax to keep prices competitive to secure formulary placement and preserve volume; losing preferred status can cut uptake by 30–60% within two years, based on recent vaccine market shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Recommendation Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Advisory Committee on Immunization Practices (ACIP) drives vaccine uptake by setting US recommendations; its guidance often translates to \u0026gt;90% of pediatric vaccine purchases by providers, so a negative or neutral ACIP stance sharply reduces Dynavax’s addressable market and sales.\u003c\/p\u003e\n\u003cp\u003eIn 2025 ACIP non-recommendation for a vaccine class can cut procurement channels and reimbursements, lowering revenue visibility and increasing market risk for Dynavax, which relies on institutional purchasing and public programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eACIP shapes \u0026gt;90% of provider purchasing\u003c\/li\u003e\n\u003cli\u003eNeutral\/negative guidance shrinks addressable market\u003c\/li\u003e\n\u003cli\u003eImpacts reimbursement and institutional procurement\u003c\/li\u003e\n\u003cli\u003eRaises revenue volatility and commercial risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFor many clinics, switching from HEPLISAV-B to rivals needs little operational change, so administrative ease and procurement price often outweigh small clinical differences.\u003c\/p\u003e\n\u003cp\u003eThat low switching cost pressured Dynavax to spend aggressively on sales and marketing—company selling, general \u0026amp; admin (SG\u0026amp;A) rose to about $87m in 2024 to defend share.\u003c\/p\u003e\n\u003cp\u003eThe result: sustained marketing spend to preserve brand loyalty and placement in purchasing contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow operational impact of switching\u003c\/li\u003e\n\u003cli\u003eProcurement price often decisive\u003c\/li\u003e\n\u003cli\u003eDynavax SG\u0026amp;A ≈ $87m (2024)\u003c\/li\u003e\n\u003cli\u003eHigh ongoing sales\/marketing need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers \u0026amp; payers squeeze vaccine pricing; Dynavax bears high SG\u0026amp;A to defend access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge institutional buyers and major pharmacy chains (60–75% and ~60% share respectively in 2024) extract steep rebates, push prices down, and can reallocate volume to rivals; payer cost-effectiveness thresholds ($50k–$150k\/QALY) and utilization management (22% vaccine claims, 2023) further constrain pricing, forcing Dynavax to sustain high SG\u0026amp;A (~$87m, 2024) to defend placement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional\/public share (2024)\u003c\/td\u003e\n\u003ctd\u003e60–75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy administration share (2024)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUtilization management (2023)\u003c\/td\u003e\n\u003ctd\u003e22% vaccine claims\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICER thresholds (2024)\u003c\/td\u003e\n\u003ctd\u003e$50k–$150k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDynavax SG\u0026amp;A (2024)\u003c\/td\u003e\n\u003ctd\u003e$87m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eDynavax Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview is the exact Dynavax Porter's Five Forces analysis you’ll receive immediately after purchase—fully formatted, professional, and ready to use with no placeholders or samples.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746720330105,"sku":"dynavax-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dynavax-five-forces-analysis.png?v=1772191242","url":"https:\/\/growthsharematrix.com\/products\/dynavax-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}